AVocAdo Extract to Improve gLycemia in Individuals With Obesity (AVAIL)

Inclusion Criteria: * Men and women 25 - 65 years old * Waist circumference (\>94cm in men and \>80cm in women) * BMI 30 - 40 kg/m2 * Willingness to provide written informed consent and willingness to participate and comply with the study Exclusion Criteria: * Women planning pregnancy during the course of the study or 3 months after completion of the study, or who are lactating * Individuals diagnosed with type 1 or type 2 diabetes mellitus, liver or kidney diseases, neoplastic disease in the previous 3 years, chronic gastrointestinal disorders (including inflammatory bowel disease and celiac), cardiovascular event in the previous 6 months, or any other condition deemed unstable * Biochemical abnormalities or evidence at screening of disease including elevated liver enzymes ALT and/or AST \>3 times normal range limit * Not weight-stable (\< 5 % fluctuation in their body weight for past 6-months at study entry). * Current or recent (within 12 months) treatment with medication used to lower blood glucose or antidiabetic medications (metformin, sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues \[i.e. exenatide\], thiazolidinediones or DPP-IV inhibitors \[i.e. 'gliptins'\]), medications affecting weight, appetite or gut motility (i.e. domperidone, cisapride, orlistat, phentermine, topiramate). Participants who are taking stable doses (i.e. \> 12 months) of androgenic medications (i.e. testosterone), thyroxine, corticosteroids, anti-depressants (selective serotonin reuptake inhibitors), anti-hypertensives (ace-inhibitors, calcium channel blockers, beta-blockers, diuretics) and lipid lowering medications (statins, fibrates) will not be excluded. * Participants who have had bariatric surgery * Participants with conditions that may interfere with the ability to understand the requirements of the study.